Literature DB >> 14666966

HMGI(Y) gene expression in colorectal cancer: comparison with some histological typing, grading, and clinical staging.

M Balcerczak1, G Pasz-Walczak, E Balcerczak, M Wojtylak, R Kordek, M Mirowski.   

Abstract

We investigated HMGI(Y) gene expression in 81 pairs of frozen samples obtained from colorectal carcinomas and adjacent normal colorectal mucosas and in four samples from colorectal mucosa from patients without neoplastic diseases. In this group, HMGI(Y)-positive/-negative expression was compared with some histological features, grading, and clinical staging of neoplasms investigated to assess its potential role as a prognostic marker for colorectal cancer. Expression of HMGI(Y) gene was found in 51 of 81 cases of colorectal cancers, while, in normal mucosa, expression of this gene was not observed. HMGI(Y) gene expression was associated with more advanced tumors (T3, T4) and metastases to lymph nodes (N1, N2). The most interesting finding was that expression of this gene correlated with distant metastases. HMGI(Y) gene expression was detected in all cases classified as M1 (n = 19, p = 0.0008). We did not find any association between age, gender, tumor localization, histological type and this gene expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14666966     DOI: 10.1078/0344-0338-00475

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  10 in total

1.  Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma.

Authors:  Siong-Seng Liau; Stanley W Ashley; Edward E Whang
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  Elevated expression of HMGA1 correlates with the malignant status and prognosis of non-small cell lung cancer.

Authors:  Ze Zhang; Quan Wang; Feng Chen; Jun Liu
Journal:  Tumour Biol       Date:  2014-10-25

3.  Gene expressions of HMGI-C and HMGI(Y) are associated with stage and metastasis in colorectal cancer.

Authors:  Meng-Lin Huang; Chou-Chan Chen; Li-Ching Chang
Journal:  Int J Colorectal Dis       Date:  2009-07-17       Impact factor: 2.571

4.  HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma.

Authors:  Siong-Seng Liau; Edward Whang
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

5.  Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer.

Authors:  Yi-Ting Wang; Szu-Hua Pan; Chia-Feng Tsai; Ting-Chun Kuo; Yuan-Ling Hsu; Hsin-Yung Yen; Wai-Kok Choong; Hsin-Yi Wu; Yen-Chen Liao; Tse-Ming Hong; Ting-Yi Sung; Pan-Chyr Yang; Yu-Ju Chen
Journal:  Sci Rep       Date:  2017-03-14       Impact factor: 4.379

Review 6.  HMGA1 in cancer: Cancer classification by location.

Authors:  Yuhong Wang; Lin Hu; Yushuang Zheng; Lingchuan Guo
Journal:  J Cell Mol Med       Date:  2019-01-07       Impact factor: 5.310

7.  Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells.

Authors:  S-S Liau; A Jazag; K Ito; E E Whang
Journal:  Br J Cancer       Date:  2007-03-06       Impact factor: 7.640

8.  Hmga1/Hmga2 double knock-out mice display a "superpygmy" phenotype.

Authors:  Antonella Federico; Floriana Forzati; Francesco Esposito; Claudio Arra; Giuseppe Palma; Antonio Barbieri; Dario Palmieri; Monica Fedele; Giovanna Maria Pierantoni; Ivana De Martino; Alfredo Fusco
Journal:  Biol Open       Date:  2014-04-11       Impact factor: 2.422

9.  Clinicopathological and prognostic significance of HMGA2 overexpression in gastric cancer: a meta-analysis.

Authors:  Jingyi Zhu; Hailong Wang; Shuangnian Xu; Yingxue Hao
Journal:  Oncotarget       Date:  2017-07-05

10.  LncRNA ITGB2-AS1 promotes the progression of clear cell renal cell carcinoma by modulating miR-328-5p/HMGA1 axis.

Authors:  Wensheng Zhang; Yigang Lu; Huibo Shi; Xungang Li; Zhuo Zhang; Xinxi Deng; Yang Yang; Bin Wan
Journal:  Hum Cell       Date:  2021-06-25       Impact factor: 4.174

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.